Group balance sheet AT 31 DECEMBER 2003 47 2003 2002 Notes m m Fixed assets Intangible assets 12 18.4 13.6 Tangible assets 13 21.0 20.0 Investments 14 1.2 1.1 40.6 34.7 Current assets C Stock 16 18.2 48.4 C Debtors: amounts receivable within one year 17 12.3 54.0 Debtors: amounts receivable after one year 18 0.1 4.9 D Short-term investments 62.0 0.1 D Cash at bank and in hand 63.2 11.7 155.8 119.1 E Creditors: amounts falling due within one year 19 96.9 88.4 Net current assets 58.9 30.7 Total assets less current liabilities 99.5 65.4 Creditors: amounts falling due after one year 20 12.3 18.9 Provisions for liabilities and charges Investment in joint venture: 21 share of assets 0.9 0.9 share of liabilities 1.2 1.1 0.3 0.2 Net assets 86.9 46.3 Capital and reserves Called-up share capital 23 10.6 9.9 Share premium account 24 96.0 87.8 Profit and loss account 24 19.7 51.4 Shareholders funds all equity 25 86.9 46.3 The accompanying notes are an integral part of this Group balance sheet.
D CASH E CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR CASH AND SHORT-TERM INVESTMENTS AT THE END OF 2003 OF THE SMALLPOX VACCINE CONTRACT.
WE EXPECT CASH CREDITORS AT THE END OF 2003 REMAIN HIGH AT 96.9M, AMOUNTED TO 125.2M, AN INCREASE OF 113.4M OVER THE LEVELS AT THE END OF 2004 WILL BE NEARER 100M AS A LARGELY IN CONNECTION WITH THE SMALLPOX VACCINE BALANCE AT THE END OF 2002.
THE SIGNIFICANT INCREASE LARGE NEGATIVE CASH MOVEMENT UNWINDS IN RELATION CONTRACT WITH THE CDC.
THE BALANCE INCLUDED ALMOST IN CASH IN 2003 IS AS A RESULT OF THE MAJORITY OF CASH TO THE SAME CONTRACT.
50M IN RELATION TO DEFERRED INCOME, REPRESENTING RECEIPTS HAVING BEEN RECEIVED FROM THE CDC IN RESPECT THE DIFFERENCE BETWEEN AMOUNTS BILLED AND RECOGNISED AS REVENUE UNDER THAT CONTRACT.
